Stock analysts at StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV – Get Free Report) in a research report issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
VBI Vaccines Stock Up 1.3 %
Shares of NASDAQ VBIV opened at $0.59 on Friday. The business’s 50 day moving average is $0.61 and its two-hundred day moving average is $0.61. The company has a market cap of $16.92 million, a P/E ratio of -0.05 and a beta of 1.90. VBI Vaccines has a 12 month low of $0.45 and a 12 month high of $3.47.
VBI Vaccines Company Profile
Further Reading
- Five stocks we like better than VBI Vaccines
- What is a Low P/E Ratio and What Does it Tell Investors?
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- 3 Warren Buffett Stocks to Buy Now
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.